Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

被引：0
作者：
M. T. Driessen
J. Whalen
B. Seewoodharry Buguth
L. A. Vallejo-Aparicio
I. P. Naya
Y. Asukai
B. Alcázar-Navarrete
M. Miravitlles
F. García-Río
N. A. Risebrough
机构：
[1] Value Evidence and Outcomes,Departamento de Evaluación de Medicamentos
[2] GSK,Pneumology Department
[3] ICON Health Economics,undefined
[4] ICON plc,undefined
[5] GSK,undefined
[6] Global Respiratory Franchise,undefined
[7] GSK,undefined
[8] Hospital de Alta Resolución de Loja,undefined
[9] Hospital Universitari Vall d’Hebron,undefined
[10] Hospital Universitario La Paz-IdiPAZ,undefined
[11] ICON Health Economics,undefined
[12] ICON,undefined
来源：
Respiratory Research | / 19卷
关键词：
Bronchodilators; Chronic obstructive pulmonary disease; Cost effectiveness; Economic evaluation; Health resources; LAMA/LABA; National Healthcare System perspective; QALY; Spain; Utility;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 242 条
[1]  
Miravitlles M(2009)Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities Thorax 64 863-868
[2]  
Soriano JB(2010)Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors Arch Bronconeumol (English Edition) 46 522-530
[3]  
Garcia-Rio F(2004)Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional Arch Bronconeumol 40 72-79
[4]  
Muñoz L(2003)Costs of chronic bronchitis and COPDa: a 1-year follow-up study Chest 123 784-791
[5]  
Duran-Tauleria E(2012)Pharmacology and therapeutics of bronchodilators Pharmacol Rev 64 450-504
[6]  
Sanchez G(2004)The role of long-acting bronchodilators in the management of stable COPD Chest 125 249-259
[7]  
Soriano JB(2013)Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease Respir Res 14 49-335
[8]  
Miravitlles M(2017)Spanish COPD guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease Arch Bronconeumol 53 324-257
[9]  
Borderías L(2012)Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD Arch Bronconeumol (English Edition). 48 247-1546
[10]  
Duran-Tauleria E(2013)Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir Med 107 1538-979
12345678910